Inventor · disambiguated record
Joanne J. Bronson
Also filed as: BRONSON JOANNE · BRONSON JOANNE J · BRONSON JOANNE JEWETT
44 granted patents·14 pending applications·992 citations·filing 1992–2023
98Inventor score
Files withBRISTOL MYERS SQUIBB CO41ACAD OF SCIENCE CZECH REPUBLIC7BI YINGZHI2PARKER MICHAEL F2UNIV VANDERBILT2
Top patents by PatentIndex Score
58 records- 0198US5792756AProdrugs of phosphonatesACAD OF SCIENCE CZECH REPUBLIC·Filed 1995·Granted Aug 11, 1998·244 cites·7 claims
- 0298US5663159AProdrugs of phosphonatesACAD OF SCIENCE CZECH REPUBLIC·Filed 1994·Granted Sep 2, 1997·336 cites·18 claims
- 0397US9902722B2Biaryl kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Feb 27, 2018·19 cites·13 claims
- 0493US5650510AAntiviral phosphonomethoxyalkylene purine and pyrimidine derivativesACAD OF SCIENCE CZECH REPUBLIC·Filed 1992·Granted Jul 22, 1997·60 cites·11 claims
- 0591US7300936B2α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Nov 27, 2007·46 cites·24 claims
- 0691US7138423B2Arylpyrrolidine derivatives as NK-1 /SSRI antagonistsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 21, 2006·10 cites·10 claims
- 0790US5744600APhosphonomethoxy carbocyclic nucleosides and nucleotidesACAD OF SCIENCE CZECH REPUBLIC·Filed 1994·Granted Apr 28, 1998·57 cites·14 claims
- 0889US5854228AAntiviral phosphonomethoxyalkylene purine and pyrimidine derivativesACAD OF SCIENCE CZECH REPUBLIC·Filed 1995·Granted Dec 29, 1998·41 cites·12 claims
- 0988US7786122B2α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 31, 2010·12 cites·1 claims
- 1087US5302585AUse of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agentsACAD OF SCIENCE CZECH REPUBLIC·Filed 1992·Granted Apr 12, 1994·32 cites·2 claims
- 1184US5391817ABiaryl phospholipase A2 inhibitorsBRISTOL MYERS SQUIBB·Filed 1993·Granted Feb 21, 1995·27 cites·26 claims
- 1283US10526323B2Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunctionUNIV VANDERBILT·Filed 2016·Granted Jan 7, 2020·2 cites·45 claims
- 1381US5620969ACephalosporin derviativesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Apr 15, 1997·24 cites·17 claims
- 1479US10544120B2Biaryl kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 28, 2020·2 cites·3 claims
- 1579US10227343B2Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunctionUNIV VANDERBILT·Filed 2016·Granted Mar 12, 2019·3 cites·27 claims
- 1679US8026257B2Substituted heterocyclic ethers and their use in CNS disordersBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Sep 27, 2011·4 cites·17 claims
- 1777US6093712ACephalosporin derivativesBRISTOL MEYERS SQUIBB CO·Filed 1998·Granted Jul 25, 2000·21 cites·9 claims
- 1876US10253027B2Aryl lactam kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 9, 2019·3 cites·6 claims
- 1976US9708337B2Aryl amide-based kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 18, 2017·3 cites·10 claims
- 2071US10246469B2Biaryl kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 2, 2019·1 cites·8 claims
- 2171US7022667B2O-derivatized nocathiacin derivativesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Apr 4, 2006·5 cites·9 claims
- 2269US9738642B2Triazolopyridine ether derivatives and their use in neurological and pyschiatric disordersBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 22, 2017·1 cites·11 claims
- 2369US8703953B2Aryl ether-base kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 22, 2014·1 cites·8 claims
- 2469US5559108ACephalosporin derivativesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Sep 24, 1996·13 cites·13 claims
- 2567US9688669B2Oxazolidinones as modulators of mGluR5BRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jun 27, 2017·1 cites·12 claims
- 2667US8901305B2Aryl lactam kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 2, 2014·1 cites·11 claims
- 2767US2024180886A1Inhibitors of protein tyrosine phosphatase, compositions, and methods of useBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2867US2024207238A1Inhibitors of protein tyrosine phosphatase, compositions, and methods of useBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2965US9932320B2Quinoline-based kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 3, 2018·1 cites·10 claims
- 3065US5436369AAlicyclic phospholipase A2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 25, 1995·9 cites·28 claims
- 3165US2025353844A1Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3265US2025263424A1Kras inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3365US2024067662A1Kras inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3464US7932256B2(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activityBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Apr 26, 2011·0 cites·2 claims
- 3564US2024228476A1Inhibitors of protein tyrosine phosphatase, compositions, and methods of useBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3664US2024238258A1Inhibitors of protein tyrosine phosphatase, compositions, and methods of useBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3759US8304577B2Modulators of G protein-coupled receptor 88DZIERBA CAROLYN DIANE·Filed 2010·Granted Nov 6, 2012·1 cites·4 claims
- 3855US7632861B2Substituted heterocyclic ethers and their use in CNS disordersBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Dec 15, 2009·0 cites·15 claims
- 3954US2016199372A1Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophreniaBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 4053US8969564B2Aryl ether-base kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 3, 2015·0 cites·3 claims
- 4151US8372847B2Pyrazinone modulator of corticotropin-releasing factor receptor activityBRISTOL MYERS SQUIBB CO·Filed 2011·Granted Feb 12, 2013·0 cites·5 claims
- 4251US2009018163A1Substituted Heterocyclic Ethers and Their Use in CNS DisordersBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 4348US5567698APyridinium thiomethyl substituted chepholosporin derivativesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 22, 1996·7 cites·16 claims
- 4447US2002065219A1Water soluble thiazolyl peptide derivativesFiled 2001·Application pending·0 cites
- 4546US9737542B2Pyrrolotriazine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 22, 2017·0 cites·7 claims
- 4646US8513253B2α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitorsPARKER MICHAEL F·Filed 2010·Granted Aug 20, 2013·0 cites·3 claims
- 4745US5696263AAntiviral acyclic phosphonomethoxyalkylsubstituted alkenyl and alkynyl purine and pyrimidine derivativesACAD OF SCIENCE CZECH REPUBLIC·Filed 1994·Granted Dec 9, 1997·3 cites·14 claims
- 4843US2016222021A1Aryl ether-base kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 4943US2016333006A1Aryl lacta kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 5042US2008027056A1Substituted heterocyclic ethers and their use in cns disordersBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →